>

NanoSyrinx highlighted in Cell Trends

Our CEO Joe Healey was recently invited to write a piece for Cell Trends’ “Industry Highlights”, which is now available online here.

These articles offer short reads about up and coming companies and technologies that are making waves in the industry. NanoSyrinx is delighted to have had the opportunity to tell our story.

The article explains why biologics are of significant pharmaceutical interest, as well as the big problems facing their utilisation – namely, drug delivery. Read on if you would like to learn more about why these classes of molecules are so promising, where NanoSyrinx believes it can help address the outstanding challenges, and to get a sense of just how successful these modalities have been already.

Read more news

Dr Valentina Galli

NanoSyrinx strengthens senior R&D team

Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities Coventry, UK, 21st January 2025: NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today […]

Read more

Meet our science and scientists at SITC and EORTC

Members from the NanoSyrinx team will be on the road over the coming weeks presenting exciting data from our internal developments and recent collaborations. If you’d like to learn more about our science and meet some of the talented folks responsible for it, come along to the sessions below. A copy of the poster can […]

Read more
Dr Edwin Moses, Chairman NanoSyrinx

NanoSyrinx closes £10 million GBP financing and appoints Dr. Edwin Moses as Chairman

Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind Appointment of Edwin Moses as Chairman to support the leadership team in maximising the value of the technology platform Novel “nanosyringe” platform can deliver complex biologic payloads selectively and […]

Read more